# Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

> **NCT04127227** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 34 (actual)

## Conditions studied

- NK/T Cell Lymphoma Nos

## Interventions

- **DRUG:** sintilimab,pegaspargase,gemcitabine,oxaliplatin

## Key facts

- **NCT ID:** NCT04127227
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-09
- **Primary completion:** 2023-07-20
- **Final completion:** 2027-10-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04127227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04127227, "Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04127227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*